Efficacy of seal-wing paclitaxel-eluting balloon catheters in the treatment of drug-eluting stent restenosis

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F18%3AE0107555" target="_blank" >RIV/00843989:_____/18:E0107555 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Efficacy of seal-wing paclitaxel-eluting balloon catheters in the treatment of drug-eluting stent restenosis

Popis výsledku v původním jazyce

Aim: Our study aimed to compare the efficacy of seal-wing paclitaxel-eluting balloon catheters (PEB) for treating drug eluting stent restenosis (DES-ISR). Methods: We enrolled 17 patients with 19 DES-ISR lesions. The control group comprised of 64 patients with bare-metal stent restenosis (BMS-ISR) from the seal-wing PEB arm of a previous TIS study. The primary end-point was 12-month in-segment late lumen loss (LLL). Secondary end-points included incidence of binary in-stent restenosis, 12-month major adverse cardiac events (MACE) and target vessel revascularisation (TVR). Results: Compared to BMS-ISR, seal-wing PEB used for DES-ISR treatment was associated with a significantly higher LLL (1.12 ± 0.83 mm vs. 0.47 ± 0.57 mm; p = 0.008), percent diameter stenosis (% DS; 62.6 ± 29.2 % vs. 42.4 ± 27.9 %; p = 0.020) and incidence of repeated binary restenosis (64.3 % vs. 28.1 %; p = 0.014). Differences at the 12-month clinical follow-up (MACE and TVR) did not reach statistical significance (50 % vs. 30 %; p = 0.077 and 43.7 % vs. 20.6 %; p = 0.103, respectively). Conclusion: Treatment of DES-ISR using seal-wing PEB was associated with significantly worse 12-month angiographic outcomes. Differences at the 12-month clinical follow-up (MACE and TVR) did not reach statistical significance.

Název v anglickém jazyce

Efficacy of seal-wing paclitaxel-eluting balloon catheters in the treatment of drug-eluting stent restenosis

Popis výsledku anglicky

Aim: Our study aimed to compare the efficacy of seal-wing paclitaxel-eluting balloon catheters (PEB) for treating drug eluting stent restenosis (DES-ISR). Methods: We enrolled 17 patients with 19 DES-ISR lesions. The control group comprised of 64 patients with bare-metal stent restenosis (BMS-ISR) from the seal-wing PEB arm of a previous TIS study. The primary end-point was 12-month in-segment late lumen loss (LLL). Secondary end-points included incidence of binary in-stent restenosis, 12-month major adverse cardiac events (MACE) and target vessel revascularisation (TVR). Results: Compared to BMS-ISR, seal-wing PEB used for DES-ISR treatment was associated with a significantly higher LLL (1.12 ± 0.83 mm vs. 0.47 ± 0.57 mm; p = 0.008), percent diameter stenosis (% DS; 62.6 ± 29.2 % vs. 42.4 ± 27.9 %; p = 0.020) and incidence of repeated binary restenosis (64.3 % vs. 28.1 %; p = 0.014). Differences at the 12-month clinical follow-up (MACE and TVR) did not reach statistical significance (50 % vs. 30 %; p = 0.077 and 43.7 % vs. 20.6 %; p = 0.103, respectively). Conclusion: Treatment of DES-ISR using seal-wing PEB was associated with significantly worse 12-month angiographic outcomes. Differences at the 12-month clinical follow-up (MACE and TVR) did not reach statistical significance.

Druh

J_SC - Článek v periodiku v databázi SCOPUS

CEP obor

—

OECD FORD obor

30201 - Cardiac and Cardiovascular systems

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Intervenční a akutní kardiologie

ISSN

1213-807X

e-ISSN

1803-5302

Svazek periodika

17

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

5

Strana od-do

206-210

Kód UT WoS článku

—

EID výsledku v databázi Scopus

2-s2.0-85058793290